Renal Cancer Studies

Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)

Study area = Kidney Cancer

Aim = The aim of the RAMPART study is to understand whether taking durvalumab alone, or in combination with tremelimumab, can prevent or delay kidney cancer coming back.

Who can participate = Any patients who have undergone surgery to remove their kidney cancer and who have a high or intermediate risk of their cancer coming back.

If you would like any further information on the following studies, and to find out if you are eligible please contact:


Address: R&D office, C254, West Wing, Broomfield Hospital, Court Road, Chelmsford, Essex, CM1 7ET

Telephone: 01245 515136
Email: Research@meht.nhs.uk 

MEDI4736 combinations in metastatic renal cell carcinoma (CALYPSO)

Area: Renal cancer 

Aim: Treatment for advanced kidney cancer is usually a biological therapy (or targeted treatment).  In this trial doctors are looking at different biological therapies:

  • MEDI4736
  • Savolitinib
  • Tremelimumab


MEDI4736 and tremelimumab are monoclonal antibodies. They seek out cancer cells by looking for particular proteins and attaching to them.  Researchers think that MEDI4736 and tremelimumab can help your immune system to attack the cancer and stop it from growing.  Savolitinib works by blocking a protein called MET.  This protein sends signals to cells telling them to divide and grow.  Blocking MET may stop cancer cells from growing.   

The main aims of this trial are to:

  • Find out how well the treatments work
  • Learn more about the side effects
  • Find out how cancer develops and who benefits from having MEDI4736, savolitinib and tremelimumab (translational research) 


Who can participate: The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you. You may be able to join this trial if all of the following apply.

  • You have a type of renal cell cancer called clear cell or sarcomatoid that has grown outside the kidney or spread to another part of the body
  • Your cancer has grown after having had drugs that block a protein called VEGF such as cabozantinib, pazopanib, sorafenib and sunitinib – if you have clear cell or sarcomatoid renal cell cancer
  • You have at least 1 area of cancer that can be seen on a CT or MRI scan and measures at least 20 mm (or 10 mm if you had a type of CT scan called a spiral CT) and it hasn’t been treated with radiotherapy. The area of cancer mustn’t be in the bones or the fluid around your tummy (abdomen), lungs or heart    
  • You are willing to have a sample of your cancer taken (a biopsy) if there is no suitable sample available
  • You have satisfactory blood tests results
  • You are able to swallow and absorb capsules
  • You have a satisfactory heart rate
  • You are well enough to carry out your normal activities, apart from heavy physical work (performance status of 0 or 1)  
  • You are at least 18 years old
  • You are willing to use reliable contraception during treatment and for 90 days after the final dose of MEDI4736 and savolitinib, if there is any possibility you or your partner could become pregnant. If you have savolitinib alone, you must use reliable contraception for 30 days after treatment